JNJ-54175446

Investigational drug for depression

JNJ-54175446
File:JNJ-54175446 structure.png
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

JNJ-54175446 is an investigational drug developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It is primarily being researched for its potential use in treating major depressive disorder (MDD) and other psychiatric disorders.

Mechanism of Action

JNJ-54175446 is a selective antagonist of the P2X7 receptor, a type of purinergic receptor that is activated by adenosine triphosphate (ATP). The P2X7 receptor is involved in the regulation of inflammation and neurotransmitter release in the central nervous system. By blocking this receptor, JNJ-54175446 may reduce neuroinflammation and modulate neurotransmitter systems implicated in depression.

Pharmacology

The pharmacological profile of JNJ-54175446 includes high selectivity and affinity for the P2X7 receptor. This selectivity is crucial for minimizing off-target effects and enhancing the therapeutic potential of the drug. The compound is designed to cross the blood-brain barrier, allowing it to exert its effects directly within the brain.

Clinical Development

JNJ-54175446 is currently in the early stages of clinical development. Initial studies have focused on its safety, tolerability, and pharmacokinetics in healthy volunteers. Subsequent trials aim to evaluate its efficacy in patients with major depressive disorder. The drug's development is part of a broader effort to explore novel mechanisms for treating depression, particularly in patients who do not respond to traditional antidepressants.

Potential Benefits

The development of JNJ-54175446 represents a novel approach to treating depression by targeting the P2X7 receptor. This mechanism may offer advantages over existing treatments, such as faster onset of action and effectiveness in treatment-resistant cases. Additionally, by reducing neuroinflammation, JNJ-54175446 could potentially address some of the underlying pathophysiological processes associated with depression.

Challenges and Considerations

While JNJ-54175446 shows promise, there are challenges associated with its development. These include the need for extensive clinical trials to establish its safety and efficacy, as well as the potential for unforeseen side effects. Furthermore, the complexity of depression as a disorder means that a single-target approach may not be sufficient for all patients.

Related Pages

• Major depressive disorder
• Purinergic receptor
• Neuroinflammation
• Antidepressant